The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > October 3, 2025
Daily News
October 3, 2025
- Moderna Reaffirms Japan Commitment, Denies Downsizing Concerns
October 3, 2025
- Regeneron Bolsters Japan Oncology Team as Libtayo Gains Ground
October 3, 2025
- Argenx Puts Japan at Core of Global Innovation Strategy
October 3, 2025
- Panel Split on Delisting OTC-Like Drugs from Insurance Coverage
October 3, 2025
- Daiichi Sankyo Opens Third Overseas Research Hub in San Diego
October 3, 2025
- Enhertu Accepted for US Review in Pre-Surgery Setting for Early Breast Cancer
October 3, 2025
- Ziftomenib Given in New AML Cohort in US PI Trial: Kura/Kyowa Kirin
October 3, 2025
- HIV Support Groups Call for Stronger Mail-In Testing System in Japan
October 3, 2025
- SanBio’s Akuugo Set for Re-Review on Oct. 16, Shipment Decision Nears
October 3, 2025
- Dayvigo, Jardiance Keep Up Strong Promotion in August: Intage
October 3, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…